Albert Lo

Title: Innovations in Cancer Treatment by Albert Lo

Introduction

Albert Lo is a prominent inventor based in Minsyong, Taiwan. He has made significant contributions to the field of molecular oncology, particularly in the development of targeted therapies for hepatocellular carcinoma (HCC). His innovative work aims to improve treatment outcomes for patients suffering from this aggressive form of cancer.

Latest Patents

Albert Lo holds a patent for "Peptides specific for hepatocellular carcinoma cells and applications thereof." This patent addresses the urgent need for novel treatment strategies for HCC, which is the fourth leading cause of cancer death worldwide. The research involved the use of phage display to identify specific peptides, including SP94, that bind selectively to HCC cells. In vitro studies demonstrated that the phage clone PC94 effectively binds to HCC cell lines. Furthermore, in vivo experiments showed that PC94 specifically targeted tumor tissues in SCID mice with human HCC xenografts, while sparing normal visceral organs. The study revealed that the homing ability of PC94 could be inhibited by the synthetic peptide SP94. Notably, PC94 was able to recognize tumor tissue in surgical specimens from HCC patients, achieving a positive rate of 61.3% (19/31). The conjugation of SP94 with liposomal doxorubicin enhanced therapeutic efficacy against HCC xenografts, leading to increased tumor apoptosis and reduced tumor angiogenesis. These findings suggest that SP94 has the potential to improve systemic treatment for patients with advanced HCC.

Career Highlights

Albert Lo is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has garnered attention for its innovative approach to cancer treatment, focusing on the molecular mechanisms underlying HCC. His research not only contributes to the scientific community but also holds promise for clinical applications that could benefit patients.

Collaborations

Albert Lo has collaborated with notable colleagues, including Han-Chung Wu and Chin-Tarng Lin. Their combined expertise has further advanced the research in targeted cancer therapies.

Conclusion

Albert Lo's innovative work in developing targeted therapies for hepatocellular carcinoma exemplifies the potential of molecular oncology to transform cancer treatment. His contributions are paving the way for improved outcomes for patients facing this challenging disease.